PHARMACEUTICAL 2019

Nanoviricides INC
Rank 48 of 361



PHARMACEUTICAL 2019

Nanoviricides INC
Rank 48 of 361

The relative strengths and weaknesses of Nanoviricides INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nanoviricides INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 151% points.The greatest weakness of Nanoviricides INC is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 374%, being 125% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	7,322
Cost of Goods Sold	0
Intangible Assets	375
Liabilities, Current	882
Liabilities, Non-Current	0
Other Assets	8.2
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	762
Other Revenues	0
Property and Equipment	10,841
Research and Development	5,914
Selling, General and Administrative Expense	3,411

Output Variable	Value in 1000 USD
Assets	18,546
Liabilities	882
Expenses	9,325
Revenues	0
Stockholders Equity	17,664
Net Income	-8,563
Comprehensive Net Income	-8,563
BaseVar	14,758
ECR before LimitedLiability	308%
Economic Capital Ratio	374%